Novilla Pharmaceuticals

The drug already worked. The delivery never did.

Somewhere in a lab off Concord Avenue in Cambridge, a computer is ruling out drug formulations by the billion. Not inventing molecules - rejecting recipes. Out of an impossible number of ways to mix and carry an established medicine, it is hunting for the one or two combinations that will slip through skin, reach inflamed tissue, and stop there. This is what Novilla Pharmaceuticals does for a living: it does not make new drugs so much as send proven ones to a better address.

Novilla is small - around 15 people - and it is unfashionably specific about its ambition. The company builds an AI drug-delivery platform that designs formulations to act at the site of the problem while keeping the rest of the body out of it. The medicine you take for pain, in their telling, has been commuting through your entire bloodstream when it only ever needed to visit one joint.

A medicine that goes everywhere does damage everywhere.

Most drugs are generous to a fault. Swallow a pill for a flare-up in one toe and the molecule floods the whole system, treating tissues that were never sick and occasionally upsetting the ones - your stomach, especially - that would have preferred to be left alone. The standard of care for gout, for instance, is famous for its gastrointestinal cost. The treatment works; the collateral is the price of admission.

That collateral has a darker cousin in pain care. Whole-body exposure is precisely what makes powerful painkillers addictive. If a drug only ever reached the site that hurt, the logic goes, it could be potent without being habit-forming. The problem was never the molecule. It was the route.

Two delivery ideas walked into a room in 2019.

Novilla began as a merger of obsessions. In 2019, Dr. Shashidhar Kori - a physician with a background in pain therapeutics and stints touching companies like GSK - joined forces with Dr. Eric Fossel, and the two folded their separate drug-delivery innovations into a single platform. Ajay Kori came on as managing director. Between them they decided that the route, not the molecule, was the frontier worth betting a company on.

The wager was unusually disciplined. Rather than chase a novel compound through a decade of discovery, Novilla would take drugs that already cleared the hard parts of biology and re-engineer how they travel. Less romance, more plumbing. The team assembled around that idea reads like a chemistry department crossed with a regulatory desk - computational chemists, product development, a scientific advisory chair, and veterans drawn from names like Allergan and Pfizer.

Founders, three. A pain physician, a delivery scientist, and the operator who keeps the lights on - the unglamorous trinity behind most biotech that actually ships.

Chemistry as a search problem.

Here is the clever part, and it is genuinely clever. Novilla treats formulation as a thing you can compute. Its platform runs what the company calls chemical-thermodynamic machine learning - models that predict how a given mix of carriers will dissolve a drug and ferry it through tissue. The carriers themselves are the interesting bit: deep eutectic solvents and ionic liquids, a class of designer fluids that can coax stubborn, water-shy drugs into solution and through the skin.

The number of possible combinations is, for practical purposes, infinite. So the AI does the rejecting. It screens billions of candidate formulations in silico and surfaces the rare one or two predicted to penetrate far deeper than conventional approaches - then those go to the bench. The delivery vehicle at the end of all this is almost anticlimactic: a non-invasive transdermal cream. You rub it on. The drug goes down, not around.

A number worth raising an eyebrow at: 212%.

Skepticism is the correct posture toward any biotech that quotes a triple-digit improvement, so here is the claim laid out plainly. Novilla's lead candidate, NOV-1776 for gout flares, reported in early human work a 212% increase in efficacy over the standard of care. It did so, the company says, with under 1% systemic exposure and zero gastrointestinal adverse events - against a standard of care known for the opposite. The candidate is described as Phase II ready.

These are early figures, not a label, and the gap between a promising 1B readout and an approved product is where most biotech optimism goes to die. But the shape of the result is exactly what the platform was built to produce: more effect where it counts, almost nothing where it doesn't.

The math of a small company. Fifteen people, nine million dollars, and a search space with more options than there are reasons to doubt them.

Aimed squarely at the opioid epidemic.

Novilla is careful about what it promises, but it is not shy about why it exists. The company's stated aim is to transform pain care and help end the opioid epidemic - the reasoning being that if a drug never floods the whole body, it loses much of what makes it addictive. Localized delivery, in this frame, is not just a side-effect story. It is a public-health argument dressed in chemistry.

It also makes Novilla a fundamentally B2B proposition. The platform's value isn't a single cream; it's a method that can be pointed at many established drugs, advanced through Novilla's own pipeline or partnered out to pharma that owns the molecules and wants a better route. The company has already taken that pitch to the industry's biggest stage, exhibiting at the BIO International Convention.

If the route is the frontier, there's a lot of map left.

The interesting thing about treating delivery as a search problem is that it generalizes. Gout is the first proof, not the destination. Every drug whose usefulness is capped by its side effects - which is to say, a great many of them - is a candidate for the same trick: same molecule, new address. That is a large and unglamorous opportunity, and unglamorous is often where the durable companies live.

The honest caveats remain. Novilla is early, lightly funded by biotech standards, and its headline numbers still have to survive larger trials and regulators who are paid to be unimpressed. But the bet is coherent in a way that is rare: it doesn't ask biology to do anything new, only to be visited more politely.

Back to that machine off Concord Avenue, still ruling out formulations by the billion. It isn't trying to be brilliant. It's trying to be precise - to find the rare recipe that reaches the one place that hurts and leaves the rest of a person out of it. Novilla's whole company is built on the idea that the most useful thing a drug can do is also the most restrained. The medicine already worked. Now it knows where to go.